文献速递眼底病与葡萄膜炎

日本地区布罗鲁珠单抗治疗后眼内炎症的发生率及危险因素:一项多中心年龄相关性黄斑变性研究

INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study.
PubMed 文献 · Retina · 2024-01-01

本研究纳入日本14家机构2020年5月至2022年5月连续接受布罗鲁珠单抗治疗的1351例新生血管性年龄相关性黄斑变性患者,眼内炎症发生率为11.3%,视网膜血管炎和/或视网膜阻塞发生率为3.9%,1年累积眼内炎症发生率为12.2%。眼内炎症(包括视网膜血管炎)和/或视网膜阻塞病史(OR 5.41,P=0.0075)及女性(OR 1.99,P=0.0004)与眼内炎症发生显著相关。

要点

  • 布罗鲁珠单抗治疗后眼内炎症发生率为11.3%,视网膜血管炎和/或视网膜阻塞发生率为3.9%。
  • 1年累积眼内炎症发生率为12.2%,30天、180天累积发生率分别为4.5%、10.3%。
  • 眼内炎症和/或视网膜阻塞病史及女性是眼内炎症发生的显著危险因素。

核心结论

  • 日本新生血管性年龄相关性黄斑变性患者接受布罗鲁珠单抗治疗的1年累积眼内炎症发生率为12.2%。
  • 眼内炎症(包括视网膜血管炎)和/或视网膜阻塞病史及女性是眼内炎症发生的显著危险因素。

研究设计与样本

  • 多中心研究,纳入日本14家机构2020年5月至2022年5月连续接受布罗鲁珠单抗治疗的1351例新生血管性年龄相关性黄斑变性患者。
  • 分析变量包括布罗鲁珠单抗注射次数、眼内炎症发生时间和危险因素。

主要发现

  • 152眼(11.3%)发生眼内炎症,53眼(3.9%)发生视网膜血管炎和/或视网膜阻塞。
  • 94例患者接受双侧治疗,其中5例(5.3%)发生双侧眼内炎症。
  • 16眼(1.2%)因视网膜血管炎和/或视网膜阻塞出现不可逆视力丧失,9眼(0.67%)视力丧失3行或以上。
  • 眼内炎症累积发生率在30天、180天和365天(1年)分别为4.5%、10.3%和12.2%。
  • 眼内炎症(包括视网膜血管炎)和/或视网膜阻塞病史与眼内炎症发生的OR为5.41(P=0.0075),女性与眼内炎症发生的OR为1.99(P=0.0004)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the incidence of intraocular inflammation (IOI) and its risk factors following intravitreal injections of brolucizumab for neovascular age-related macular degeneration in Japan. METHODS: A total of 1,351 Japanese consecutive patients with neovascular age-related macular degeneration who were treated with brolucizumab from May 2020 to May 2022 at 14 institutions were examined. The variables analyzed were the number of brolucizumab injections, time to onset of IOI, and risk factors. RESULTS: Intraocular inflammation developed in 152 eyes (11.3%). Retinal vasculitis and/or retinal occlusion occurred in 53 eyes (3.9%). Ninety-four patients received bilaterally, bilateral IOI occurred in five patients (5.3%). Sixteen eyes (1.2%) had irreversible visual acuity loss and nine eyes (0.67%) had visual loss of three lines or more due to retinal vasculitis and/or retinal occlusion. The cumulative IOI incidence was 4.5%, 10.3%, and 12.2% at 30, 180, and 365 days (1-year), respectively. History of IOI (including retinal vasculitis) and/or retinal occlusion (odds ratio [OR], 5.41; P = 0.0075) and female sex (OR, 1.99; P = 0.0004) were significantly associated with IOI onset. CONCLUSION: The 1-year cumulative incidence of IOI in Japanese neovascular age-related macular degeneration patients treated with brolucizumab was 12.2%. History of IOI (including retinal vasculitis) and/or retinal occlusion and female sex were significant risk factors.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Inoda S, Takahashi H, Maruyama-Inoue M, et al. INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study. Retina. 2024. PMID: 38016089. doi:10.1097/IAE.0000000000004009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。